Orphazyme

There are three parts to the AIDNPC program:

The company's team recognizes patients who have participated in or are enrolled in its clinical trials and says their contributions are essential to research on NPC and Gaucher disease.

The company studies the cell-protective properties of heat shock proteins (HSPs) and aims to translate this science into treatments for rare neurodegenerative diseases.

News/2024/Company-announcement-13_2024-The-company-initiates-an-identity-change-with-Nasdaq-and-explores-the-possibility-of-expanding-its-corporate-purpose-clause. pdf

News/2024/Selskabsmeddelelse-1_2024-Andring-af-nominel-aktiekapital. pdf

Orphazyme is a development-stage biopharmaceutical company developing therapeutic approaches to severe diseases and collaborating with the research community worldwide.

The company is a global drug development company with offices in Denmark, Switzerland, and Chicago, USA. Its employees represent dozens of countries and languages.

Experience heading out-licensing, acquisitions, in-licensing etc.

Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.

Orphazyme was founded in Denmark in 2009, based on research about heat shock proteins published in Nature. Thomas Kirkegaard Jensen, a lead author of the article, is a company founder and its chief scientific officer.

Michael Hove, Chairman of the Board, Orphazyme A/S Email: [email protected] Phone: +45 28 12 66 09

Orphazyme was founded in 2009 and listed at Nasdaq Copenhagen in 2017. The company focused on research and development of novel therapeutics for neurodegenerative diseases, such as Niemann Pick disease type C (NPC).

Orphazyme develops therapies for lysosomal storage diseases and was founded in June 2009, based on discoveries from the academic laboratory of its scientific founders.

www.orphazyme.com (the “Website”) is provided and owned by: Orphazyme A/S Lyskær 8A DK-2730 Herlev Denmark CVR no: 32266355 Phone: +45 28126609 E-mail: [email protected]

Orphazyme US, Inc. owns the website, and its use of cookies may involve processing personal data.

Data controller: Orphazyme A/S Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark [email protected] (“Orphazyme”)

The statement describes Orphazyme US, Inc.'s practices for handling information it collects.

This website is owned by Orphazyme A/S, Ole Maaløes Vej 3, 2200 Copenhagen N, Denmark (“Orphazyme”)

The page sets out terms and conditions for accessing and using the website and its services.